**SUPPLEMENTARY FIGURES**

**Supplementary Figure 1**

Kaplan-Meier curves showing progression free survival (PFS, A) and overall survival (OS, B) according to the expression of the LKB1 marker: negative/weak immunohistochemistry expression of LKB1 *versus* moderate/high expression of the marker.

**Supplementary Figure 2**

Kaplan-Meier curves showing overall survival according to treatment (panels A-B) or expression of the LKB1 marker (panels C-D) in patients with non-squamous tumor histology.

**Supplementary Figure 3**

Immunohistochemistry analysis of LKB1 and phosphorylated AMPK (pAMPK) expression in tumor samples. The panels show that loss of LKB1 is associated with reduced pAMPK levels.

**Supplementary Figure 4**

Kaplan-Meier curves for progression-free survival (PFS; A) and overall survival (OS; B) of the overall study population according to treatment with or without bevacizumab.







